Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim President and Chief Executive Officer Jim Ziegler – Executive Vice President-Commercial Igor Bilinsky – Chief Operating Officer Jean-Marc Bellemin – Chief Financial Officer Friedrich Finckenstein – Chief Medical Officer Brian Gastman – Executive Vice President-Medical Affairs Conference Call Participants Michael Yee – Jefferies Peter Lawson – Barclays Andrea Tan – Goldman Sachs Yanan Zhu – Wells Fargo Securities Tyler Van Buren – TD Cowen Ben Burnett – Stifel Colleen Kusy – Baird Asthika Goonewardene – Truist Reni Benjamin – Citizens JMP Operator Welcome to the Iovance Biotherapeutics Conference Call to discuss Second Quarter 2024 Results and Recent Corporate Updates. My name is Daniel and I will be your operator for today's call.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.47 per share a year ago.
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
An analyst from Piper Sandler recently downgraded Iovance Biotherapeutics and lowered the firm's price target on the stock The FDA approved Iovance's first drug in February, and investors still aren't sure if its commercial launch can succeed. An ongoing clinical trial could greatly expand the addressable patient population for the company's lead drug.
Why Iovance Biotherapeutics Stock Stumbled Today
An analyst downgraded his recommendation on the biotech. In spite of that, these are exciting times for Iovance.
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
Piper Sandler downgraded Iovance Biotherapeutics Inc IOVA, citing the slow launch of Amtagvi (lifileucel), a prescription medicine used to treat adults with a type of skin cancer that cannot be removed surgically or has spread to other parts of the body called unresectable or metastatic melanoma.
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.
The cost of taking out fresh debt is an important consideration for some biotechs. There's reason to believe that debt financing is about to get a bit cheaper.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Is Iovance Biotherapeutics a Millionaire Maker?
Iovance Biotherapeutics just launched its first therapy. Its revenue is likely to start ramping up.
Is It Too Late to Buy Iovance Biotherapeutics Stock?
Iovance's shares took off earlier this year after its cell therapy obtained accelerated approval. The company, however, still remains deeply unprofitable and is burning through cash at a high rate.
